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Background: The aim of the present study was to enhance a topical delivery of hirsutenone 
(HST), a naturally occuring immunomodulator, employing Tat peptide-admixed elastic 
  liposomes (EL/T).
Methods: HST-loaded EL, consisting of phosphatidylcholine and Tween 80 (85:15 w/w%), were 
prepared using thin film hydration method. By adding Tat peptide to EL (0.16 w/w%), EL/T 
were formulated. The in vitro skin permeation of HST was examined using a Franz diffusion 
cell mounted with depilated mouse skin. Lesions for atopic dermatitis (AD) were induced by 
a topical application of diphenylcyclopropenone to NC/Nga mice. Therapeutic improvements 
of AD were evaluated by clinical skin severity scores. Immunological analyses on inducible 
nitric oxide synthase and cyclooxygenase-2 levels in the skin and interleukin (IL)-4, IL-13, 
immunoglobulin E, and eosinophil levels in the blood were also performed.
Results: EL systems were superior to conventional cream, revealing greater flux values in a 
permeation study. The addition of Tat peptide further increased the skin permeation of HST. In an 
efficacy study with AD-induced NC/Nga mice, an HST-containing EL/T formulation brought a 
significant improvement in both skin severity score and immune-related responses for the levels 
of nitric oxide synthase, cyclooxygenase-2, IL-4, IL-13, immunoglobulin E, and eosinophils.
Conclusion: A novel EL/T formulation was successfully developed for topical delivery of 
HST to treat AD.
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Introduction
Patients with atopic dermatitis (AD), a chronically relapsing inflammatory skin disease, 
suffer from allergic symptoms such as redness, flaking, and itching.1 The causes of 
AD are not completely understood, but complex inflammatory immune dysregulation 
and susceptible responses to environmental allergens are believed to be involved.2 
AD is characterized by type 2 helper T cell (Th2)-dominated immunity that leads to 
elevated levels of serum immunoglobulin E (IgE) and peripheral eosinophils.2,3 It is 
also indicated by increased inflammatory enzymes including inducible nitric oxide 
synthase (iNOS) and cyclooxygenase-2 (COX-2) in the skin. Topical corticosteroids 
as immunosuppressors have been used for over 50 years as first-line therapy for AD, 
but their side effects, including skin atrophy and striae, are major obstacles for long-
term application.4 Alternatively, many potential compounds originating from natural 
sources such as olive oil, omega oils, royal jelly, and magnolol have been widely 
investigated to develop a natural remedy for AD.5−8
Hirsutenone (HST), 1,7-bis-(3,4-dihydroxyphenyl)-4-heptene-3-one, is one of the 
major diarylheptanoids isolated from the bark of Alnus japonica.9 Hirsutenone   inhibits International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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12-O-tetradecanoylphorbol-13-acetate (TPA)-induced 
COX-2 expression and the synthesis of prostaglandin E2 in 
human mammary epithelial MCF 10A cell lines.10 A recent 
study revealed that HST reduced the production of cytokine 
mRNAs such as interleukin (IL)-2, 4, 5, 13, and interferon-γ 
after T-cell receptor stimulation and, remarkably, suppressed 
the degranulation of mast cells, indicating the feasibility of 
HST as a new topical drug candidate for AD therapy.11 By 
virtue of its lipophilic nature, HST could be actively trans-
located into cells. However, because of the water-insoluble 
properties of HST, solubilization and incorporation of the 
drug are necessary for topical formulation development. 
In addition, a penetration-enhancing system is required to 
achieve therapeutic concentrations to deeper skin layers of 
the epidermis and/or dermis.
Several methods to enhance skin delivery have been 
explored by employing chemical enhancers, creams, vesicu-
lar carriers, ultrasound aids, and the use of microneedles.12−14 
It was found that elastic liposomes (EL), a phospholipid 
vesicular system containing edge activators, were very 
effective in enhancing the dermal and/or transdermal 
deliveries of both lipophilic and hydrophilic molecules. 
Compared with the conventional liposomes, EL are able to 
respond to an external stress by rapid shape transformation 
and can penetrate the skin efficiently in terms of quantity 
and depth.15,16 Researchers have proposed that these lipo-
somal vesicles could improve the skin delivery of drugs 
by one of the following mechanisms: intact vesicular skin 
penetration, a penetration enhancing effect, or penetra-
tion of liposomes through the transappendageal route.17,18 
Another pharmaceutical approach to enhance skin delivery 
is to employ cell-penetrating peptides. Some experiments 
have demonstrated that cell-penetrating peptides including 
YARA, WLR, R9, and Tat (Trans-activating transcriptional 
activator) peptides were useful not only for intracellular 
delivery but also for promoting the skin penetration of 
molecules in mice.19,20 A recent study showed that Tat 
peptide facilitates the translocation of drugs into immune 
cells in the skin.21
Therefore, a novel Tat peptide-admixed EL (EL/T) con-
taining HST was developed. The in vitro skin permeation 
properties and in vivo therapeutic efficacy of this formulation 
were then compared with other formulations of either the 
cream type or an EL system. Therapeutic improvements of 
AD in NC/Nga mice were evaluated by clinical skin severity 
scores. The immunological analyses of suppression levels 
for iNOS, COX-2, IL-4, IL-13, IgE, and eosinophil were 
also conducted.
Materials and methods
Animals
Male 5-week-old ICR mice and female 5-week-old NC/Nga 
mice were purchased from Orient Bio (Kyungki-Do, Korea) 
and Charles River (Yokohama, Japan), respectively. 
They were maintained for 2 weeks before the start of the 
experiments and were housed in an air-conditioned animal 
room with a 12-hour light–dark cycle (08:00–20:00 hours 
light, 20:00–08:00 hours dark) at a controlled temperature 
of 23°C ± 2°C and humidity of 50% ± 10%. Mice were 
provided with a laboratory diet and water ad libitum. All 
animal experiments were performed in accordance with the 
National Institutes of Health (NIH) Principles of Laboratory 
Animal Care guidelines (NIH publication No. 85-23, revised 
1996) and were approved by the Institutional Animal Care 
and Use Committee of Chung-Ang University in Seoul, 
South Korea.
chemicals and reagents
Hirsutenone (purity .95% by high-performance liquid 
chromatography [HPLC]) was provided from Chung-Ang 
University Pharmacognosy Laboratory (Seoul, South Korea). 
Soybean phosphatidylcholine (PC), cholesterol, Tween 80, 
phosphate-buffered saline (PBS) tablets, butylated hydroxy-
toluene (BHT), and N,N-diethylnicotinamide (DENA) 
were purchased from Sigma Aldrich (St Louis, MO). Tat 
peptide (Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg, 9 mer) 
was synthesized from Peptron Co (Taejun, South Korea). 
Polyglyceryl-3-methylglucose distearate, stearic acid, cetyl 
alcohol, mineral oil, and glycerin used for cream preparation 
were kindly provided by LG Life Science Ltd (Seoul, South 
Korea). Sodium carboxymethylcellulose was purchased from 
Duksan Pure Chemical Co (Kyungkido, South Korea). All 
other chemicals and reagents were purchased from commer-
cial sources and were of analytical grade. Doubly distilled 
water was used for all experiments.
Preparation of topical formulations
Preparation of eL formulations
HST-loaded EL were prepared using a previously published 
thin-film hydration method.22 Briefly, PC and Tween 80 
(85:15 w/w%) were dissolved in chloroform and methanol 
(1:1) in a round-bottom flask. After dissolving HST, the 
organic solvent was removed by rotary vacuum evapora-
tion above the lipid transition temperature and solvent 
traces were removed under nitrogen gas. The lipid film 
was then hydrated with distilled water containing an anti-
oxidant (BHT 0.005 w/v%) to prevent drug oxidation and International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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then   sonicated in a bath sonicator (model 2210, Branson 
Ultrasonics Co, Danbury, CT) for 20 minutes. Tat-admixed 
EL (EL/T) were formulated by adding Tat peptide to EL at 
a concentration of 0.16 (w/w%), equivalent to the peptide 
to lipid molar ratio of 0.1:100. The final lipid concentration 
in all vesicular formulations was 13 mg/mL, and the drug 
concentration was 1.0 w/w%. A thickening agent, sodium 
carboxymethylcellulose, was added to both EL formulations 
at a concentration of 0.5 w/w% to improve the application of 
formulations to the postaxial back of the mouse.
Preparation of cream formulations
A conventional oil-in-water type cream (CC) containing 
1.0 w/w% HST was prepared as follows. Water-insoluble HST 
was dissolved in an oil phase consisting of mineral oil (7%), 
stearic acid (5%), cetyl alcohol (2%), and BHT (0.005%), 
with polyglyceryl-3-methylglucose distearate (3%) used as 
an emulsifier. The aqueous phase consisted of glycerin (10%) 
and distilled water. The oil phase was added to the aqueous 
phase and then homogenized for 10 minutes, degassed, and 
cooled under vacuum. Tat-admixed conventional cream 
(CC/T) was prepared by mixing Tat peptide into CC at a con-
centration of 0.16 w/w% and rehomogenizing for 3 minutes. 
Both cream formulations were then stored for about 24 hours 
before subjected to evaluation.
Physical characterization  
of eL formulations
size and zeta potential
Liposomal vesicles were diluted with an appropriate vol-
ume of water and were examined for size distribution and 
zeta potential using a dynamic light scattering particle 
size analyzer (Zetasizer Nano-ZS; Malvern Instruments, 
  Worcestershire, UK) with a 50 mV laser at a scattering angle 
of 90°. All measurements were carried out under ambient 
conditions and in triplicate.
Loading efficiency
Unencapsulated drug was separated from the liposomes by 
centrifugation at 15,000 rpm for 10 minutes.23 The supernatant 
was analyzed for HST by HPLC. The entrapment   efficiency 
of the liposomes was calculated by [(T − C)/T] × 100, where 
T is the total amount of drug initially added, and C is the 
amount of drug detected in the supernatant.24
elasticity of the vesicle membrane
The vesicle suspension was driven through a microporous 
filter by an external pressure of 2.5 bars.25 The size of the 
vesicles was monitored using dynamic light scattering 
measurement before and after filtration. The elasticities of 
the vesicle membranes were calculated using the previously 
reported formula: D = J × (rv/rp),2 where D is the deformabil-
ity index of the vesicle membrane, J is the amount of vesicle 
suspension extruded for 5 min, rv is the size of the vesicle 
after extrusion, and rp is the pore size of the barrier.26
In vitro skin permeation study
solubilization of hsT for sink conditions
To maintain the sink conditions in the receptor compartment 
for HST, DENA was selected as a hydrotropic agent for 
solubilization of the hydrophobic drug.27 An excess amount 
of HST was added to PBS containing various concentra-
tions of DENA and then vortexed. The mixture was shaken 
intermittently at ambient temperature for 24 hours to reach 
equilibrium. The supersaturated sample was centrifuged 
at 12,000 rpm for 10 minutes to separate the undissolved 
HST. The supernatant was then filtered through a 0.45 µm 
membrane filter (Whatman, Piscataway, NJ) and diluted with 
methanol for the HST assay by HPLC.
skin permeation of hsT
An in vitro permeation study was conducted with vertical 
Franz diffusion cells as previously described.18,28 Skin tissues 
were obtained from hairy ICR mice, from whom the dorsal 
hair of the mouse skin was carefully removed using electric 
clippers and rinsed with phosphate buffer. A circular piece 
of dorsal skin was then carefully mounted onto the receiver 
compartment of the diffusion cells with the stratum corneum 
facing toward the donor compartment. The receptor compart-
ment was filled with 10 mM PBS (pH 7.4) solution containing 
1.5 M DENA and was maintained at 32°C. Each formula-
tion containing the equivalent amount of HST (5.0 mg) was 
applied to the skin surface, which had an available diffusion 
area of 1.76 cm2. The aliquots (0.5 mL) were withdrawn at 
predetermined time intervals and analyzed by HPLC. The 
cumulative amount of drug permeated per unit area was plot-
ted as a function of time. The steady-state permeation rate 
(Jss) and lag time (TL, hours) were calculated from the slope 
and X-intercept of the linear portion, respectively.
hsT assay by hPLc
The quantitative determination of HST was performed by 
HPLC using acetonitrile-0.3% acetic acid in water (25:75) 
as a mobile phase at a flow rate of 1 mL/minute. The 
HPLC   system consisted of a pump (L-2130), a UV detector 
(L-2400), a data station (LaChrom Elite, Hitachi, Japan), International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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and a 15 cm C18 column (Shiseido, Tokyo, Japan). The 
  column eluant was monitored at 220 nm, and the HST peak 
was separated at a retention time of 12.0 minutes.
In vivo efficacy and immune-related  
responses
Induction of AD in mice and the topical application 
of hsT
AD-like lesions were induced by a topical application of diphe-
nylcyclopropenone (DPCP), a well-known contact allergen, to 
NC/Nga mice as previously described.29 The mouse skin was 
stimulated for 10 weeks by 0.1% DPCP solution under ambient 
conditions. AD was characterized by itching, erythema, and 
hemorrhage, followed by edematous superficial erosion, deep 
excoriation, scaling, and dryness of the skin.30 For topical appli-
cation, regrown hairs on the postaxial backs of the mice were 
removed a day before the experiment. The mice were treated 
daily for 4 weeks with drug-free CC base alone (control) or 
drug-containing topical formulations of CC/T and EL/T.
clinical observation of skin severity
The clinical severity of dermatitis was assessed in a blinded 
fashion using a previously described method.8,29 A total score 
for skin severity was defined as the sum of the individual 
scores, graded as 0 (no lesion), 1 (mild lesion), 2 (moderate 
lesion), and 3 (severe lesion), for each sign and symptom, 
such as erythema, edema, oozing or crust, excoriation, 
lichenification, and dryness.
Measurement of iNOs and cOX-2 levels in skin
Mice were sacrificed at 4 weeks after HST treatment. An 
area of approximately 1.5 × 1.5 cm2 was excised, and the 
subcutaneous fat and blood vessels were carefully dissected 
away. Expression levels of iNOS and COX-2 in the skin were 
measured by Western blotting.31 Skin tissues were lysed in a 
buffer containing 50 mM tris(hydroxymethyl)amino   methane, 
150 mM sodium chloride, 0.02% sodium azide, 100 µg/
mL phenylmethanesulfonyl fluoride, 1% Triton X100, and 
1 µg/mL aprotinin. After centrifugation, the supernatant was 
loaded onto a 15% sodium dodecyl sulfate polyacrylamide 
gel and electrophoresed. For iNOS and COX-2 detections, 
the electrophoretically resolved proteins were transferred 
onto nitrocellulose membranes (Osmonics, Milwaukee, WI). 
The membrane was incubated with anti-iNOS and COX-2 
polyclonal antibodies (1:1000 in 5% bovine serum albumin 
[Chemicon, Temecula, CA]) and then washed three times 
with a Triton X100-containing PBS   solution. Relative   protein 
levels were measured using scanning densitometry of the 
band intensities in the immunoblots after visualization of 
protein with an enhanced chemiluminescence detection kit 
(ECL Advance Western Blotting Detection Kit; Amersham 
Pharmacia Biotech, UK).
Measurement of IL-4, IL-13, Ige, and eosinophil  
levels in blood
The amounts of IL-4, IL-13, IgE, and eosinophil in treated 
mouse blood were quantified according to a previously 
described method.32 Blood was collected from the retro-
orbital plexus of mice under ether anesthesia. Serum was 
obtained by centrifugation of whole blood at 12,000 rpm 
and was stored at −20°C until use. The levels of IL-4 and 
IL-13 were measured using a mouse IL-4 ELISA kit and 
a mouse IL-13 ELISA kit (R&D Systems, Minneapolis, 
MN). The amount of total IgE in the serum was determined 
using a mouse IgE ELISA kit. An eosinophil count was 
conducted on 30 µL of capillary blood diluted sixfold with 
saline. Microscopic differential counts were performed on 
Wright–Giemsa-stained blood smears. Eosinophil counts 
were calculated from the differential counts.
statistical analysis
All data are expressed as mean ± standard deviation.   Statistical 
significance was checked by t-test and was considered to be 
significant at P , 0.05, unless otherwise indicated.
Results and discussion
characteristics of topical formulations
EL formulations were characterized by vesicular size, 
zeta potential, loading efficiency, and deformability index. 
  Vesicular size was measured on average at 130–150 nm, 
which is considered as an ideal size for skin delivery.33 Surface 
charges in the EL were measured at about –30 mV but were 
neutralized by the addition of Tat peptide to about –10 mV due 
to electrostatic adhesion of the cationic peptide to the vesicular 
surface. EL formulations showed a high loading efficiency 
of HST over 70%. HST was efficiently encapsulated into the 
liposome due to its lipophilicity. In comparison, liposomal 
encapsulation of oregonin, a hydrophilic diarylheptanoid as 
a glycoside form, has been shown to be markedly lower than 
that of HST.34 The deformability index of EL, a crucial feature 
of elastic liposomes for skin penetration enhancement, was 
observed at about 60, which is a three- to fourfold greater 
value than that of conventional liposomes.14,34 The incorpo-
ration of an edge activator, Tween 80, destabilized the lipid 
bilayers, thereby increasing the deformability of the vesicles.35 
The   stress-dependent   adaptability of EL imparts an exclusive International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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ability to pass through the skin barrier with ease, which in turn 
provides an   adjuvant effect for HST permeation. Conventional 
oil-  in-water type cream formulations were prepared success-
fully and appeared as white, opaque, homogeneous semifluids 
with no bleeding or phase separation. HST was solubilized in 
the oil phase, and no drug crystals were observed. Under the 
presence of the antioxidant BHT (0.005%), the drug contents 
in all formulations were maintained at over 98% during the 
experimental period.
sink conditions for skin permeation study
Although physiological saline was potentially the most 
appropriate receptor phase, an appropriate solubilizing agent 
was required to provide a sufficient solubility for HST and to 
maintain the sink conditions during the permeation   studies. 
The aqueous solubility of HST was increased by several 
orders of magnitude in the presence of DENA, a novel hydro-
tropic agent (Figure 1). The increased solubilization might 
be attributed to the complexation of DENA with the drug 
molecule, alterations in the nature of water as a solvent, and 
self-associations in aqueous solution at high concentration 
of the hydrotropic agent (.1 M).36,37 In particular, a medium 
with 1.5 M DENA provided about 6 mg/mL of HST   solubility. 
This equilibrium solubility guarantees the sink conditions for 
HST, because the total amount of HST in the donor phase was 
5 mg, and the volume of the receptor phase was 11 mL in the 
Franz diffusion cell.
Skin permeation profiles of HST
The in vitro permeation profiles of HST in various topical 
formulations, including CC, CC/T, EL, and EL/T, are shown 
in Figure 2. Permeation of HST in conventional creams was 
significantly lower than those of the liposomal formulations. 
The slope of the EL/T formulation was much steeper than 
those of the other formulations. The order of HST penetration 
at 24 hours was as follows: EL/T . EL . CC/T . CC. The 
skin permeation parameters of HST from liposomal and non-
liposomal formulations are summarized in Table 1. Compared 
with cream formulations, liposomal formulations revealed 
greater values in flux and cumulative amount permeated at 
24 hours. However, incorporation of the drug into liposomes 
resulted in skin permeation time lag because of the required 
time for HST-containing liposomal nanovesicles to migrate 
from the gel matrix of the vehicle. In particular, EL/T formula-
tion significantly increased the amounts of HST permeated (%): 
1.7-fold versus EL, 2.7-fold versus CC/T, and 4.1-fold versus CC. 
It was determined that EL systems were superior to cream 
formulations and that the addition Tat peptide even further 
improved topical delivery of HST.
In looking further into the details of flux values for differ-
ent formulations, formulation effects on the skin permeation 
of HST for two variables were noticed: EL formulation and 
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mouse skin for 24 hours.
Note: Values represent mean ± standard deviation, n = 3.34
Abbreviations: cc, conventional cream; cc/T, Tat-admixed conventional cream; 
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Table 1 Permeation parameters of hsT in various formulations 
through depilated mouse skin (mean ± standard deviation, n = 3)
CC CC/T EL EL/T
Jss (µg/h/cm2)a 4.88 ± 0.49 7.37 ± 1.55 13.33 ± 1.69 22.63 ± 1.62
Permeated (%)b 3.80 ± 0.45 5.74 ± 1.32   8.99 ± 1.18 15.48 ± 1.31
TL (h)c 2.12 ± 0.34 2.13 ± 0.69   4.92 ± 0.41   4.83 ± 0.28
Notes: aFlux was obtained from the slope of the permeation profile in Figure 2; 
bcalculated from the cumulative amount permeated at 24 hours divided by the 
amount of drug loaded into the samples; cLag time calculated from the X-intercept 
of the linear portion.
Abbreviations: hsT, hirsutenone; cc, conventional cream; cc/T, Tat-admixed cc; 
eL, elastic liposomes; eL/T, Tat-admixed eL.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Tat peptide addition (Figure 3). The enhancement ratio was 
expressed as a relative ratio of the flux values. EL and EL/T 
showed enhancement ratios of 2.7 and 3.1 versus CC and 
CC/T, respectively. The high, stress-dependent transform-
ability of EL enabled them to travel between the cells in 
the stratum corneum, which effectively allows them to 
pass through the intact skin spontaneously under the influence 
of the naturally occurring transcutaneous hydration gradient. 
A previous study has shown that EL rapidly enters the deeper 
layers of the stratum corneum and can reach layers almost as 
deep as the stratum corneum-viable epidermal junction.15,38 
However, the addition of Tat peptide further intensified the 
skin penetration-enhancing capacity of EL. EL/T exhibited an 
enhancement ratio of 1.7 versus that of EL, which followed 
a similar trend to the cream formulations. This result is con-
sistent with an earlier report that stated that the noncovalent 
WLR fragment, one of the penetrating   peptides, was twice 
as effective in promoting the penetration of macromolecules 
into the skin.19 It is also supported by an earlier report stat-
ing that several penetrating peptides are able to interact 
with lipids in the stratum corneum and enter into a layer of 
cells via a macropinocytosis mechanism, forming a gradient 
from the outer to the inner cell layers, thus facilitating the 
delivery of drug.39
In vivo therapeutic efficacy for skin 
severity
To evaluate the therapeutic efficiency of HST-loaded EL/T 
and CC/T formulations for AD severity in vivo, AD-like 
lesions were artificially induced in NC/Nga mice. Mice 
with AD-like lesions manifested with severe pruritis, 
  dryness, and eczema, showing no significant differences in 
severity level between mice. AD-like lesions on the dorsal 
skin in the control group presented as a reddish-colored 
wound and dried skin even after 4 weeks. Compared with 
the normal group, the HST-treated groups showed con-
siderable reductions in these symptoms, demonstrating 
complete recovery within 4 weeks following treatment 
(Figure 4). Evaluation of AD scoring (SCORing Atopic 
Dermatitis) for skin severity (Figure 5) showed that both 
EL/T and CC/T formulations started to show significantly 
different improvements within a week, and that the   values 
continued to reduce gradually for up to 4 weeks. The 
EL/T-treated group revealed the best result with complete 
recovery within 2 weeks following topical application, a 
significant difference (P , 0.05) from that of the CC/T 
treatment. The superiority of the EL/T formulation cor-
related very well with the in vitro skin permeation results. 
This trend in formulation differences was maintained for 
3 weeks after treatment, even though there was a small 
decrease in score values. However, at 4 weeks after treat-
ment, there were no significant differences between the 
EL/T- and CC/T-treated groups. It is therefore concluded 
that the EL/T formulation brought about a rapid and pro-
found improvement as an AD therapy.
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suppression of iNOs and cOX-2  
levels in skin
Diarylheptanoids including HST have been shown to promote 
antioxidant effects through scavenging actions on superox-
ides and 1,1-diphenyl-2-picrylhydrazyl radicals.40 These 
compounds prevent the expressions of iNOS and COX-2 in 
RAW264.7 macrophages in a dose-dependent manner.10 
Both HST-treated groups resulted in marked declines in both 
iNOS and COX-2 expression levels (Figure 6), which were 
significantly different (P , 0.05) from those of the control. 
Although a more than 50% reduction in expression levels 
was obtained using the CC/T treatment, the EL/T treatment 
decreased the levels even further to about 30%, revealing 
significant differences between the two treatment groups. 
In accordance with the clinical observations of skin sever-
ity, the entrapment of the drug in an EL/T system facilitated 
the transfer of HST to skin and thereby increased the anti-
inflammatory activity of the drug.
suppression of IL-4, IL-13, Ige  
and eosinophil levels in blood
In the present study, repeated treatment with DPCP in 
NC/Nga mice triggered IgE and eosinophil hyperproduction 
with upregulation of IL-4 and IL-13. All immune response 
levels were greatly elevated in the control group, in which 
the elevation remained constant even after 4 weeks of treat-
ment with drug-free cream base (Figure 7). Studies of 
NC/Nga mice with AD symptoms have also demonstrated 
the elevation of immune responses, including IL-4, IL-13, 
IgE, and eosinophil levels.41−43 The increased serum IgE level 
would be driven from the Th1/Th2 imbalance skewed to 
Th2, in which Th2 cytokines such as IL-4 and IL-13 play 
key roles in the hyperproduction of IgE.44 In addition, 
leukotrienes generated by eosinophils amplify inflamma-
tory cascades by acting as chemotactic factors or by trig-
gering the release of cytotoxic proteins.45,46 Meanwhile, 
HST   treatment with CC/T or EL/T formulation brought 
remarkable and significant reductions in all levels to less 
than half of that of the control (P , 0.05), revealing the 
effectiveness of HST for AD therapy. However, unexpect-
edly, there were no significant differences between the two 
treatment groups in the suppression levels for IL-4, IL-13, 
IgE, or eosinophils. These results might be due to the fact 
that expression levels of these parameters were mostly nor-
malized in NC/Nga mice after 4 weeks of HST application 
regardless of its formulation.
0
0
2
4
6
8
10 Control CC/T EL/T
12
Time (week)
S
k
i
n
 
s
e
v
e
r
i
t
y
 
s
c
o
r
e
34
*
*
*
*
* * * **
* **
Figure 5 changes in skin severity score after topical application of hsT formulations: 
control, CC/T and EL/T. A total score for skin severity was defined as the sum of 
the individual scores, graded as 0 (none), 1 (mild), 2 (moderate), and 3 (severe), 
for each sign and symptom, such as erythema, edema, oozing or crust, excoriation, 
lichenification and dryness.
Notes: Bar represents standard deviation (n = 3), and the statistical analysis was 
performed using the t-test (*P , 0.05 versus control; **P , 0.05 versus cc/T).34
Abbreviations:  cc/T,  Tat-admixed  conventional  cream;  eL/T,  Tat  peptide-
admixed elastic liposomes; hsT, hirsutenone.
0.0
Control
COX-2
Actin
82 kDa
42 kDa
C
O
X
-
2
/
a
c
t
i
n
 
×
 
1
0
0
CC/T EL/T
0.1
0.2
0.3
0.4
0.5 B
*
**
*
0.0
Control
iNOS
Actin
130 kDa
42 kDa
i
N
O
S
/
a
c
t
i
n
 
×
 
1
0
0
CC/T EL/T
0.1
0.2
0.3
0.4
0.5
0.6 A
*
** *
Figure 6 Alterations of (A) iNOs and (B) cOX-2 levels in Nc/Nga mouse skin 
after topical application of hsT formulations: control, cc/T and eL/T.
Notes: The levels were determined by Western blotting. Bar represents sD (n = 3), 
and the statistical analysis was performed using the t test (*P , 0.05 versus control; 
**P , 0.05 versus cc/T).34
Abbreviations:  cc/T,  Tat-admixed  conventional  cream;  eL/T,  Tat  peptide-
admixed elastic liposomes; hsT, hirsutenone.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2466
Kang et al
Conclusion
A major obstacle to achieving therapeutic effectiveness is 
delivery of the pharmacologically active agent to its site of 
action. The results of this study show that elastic liposomal 
formulations can be advantageous for the topical delivery 
of HST, a naturally occurring lipophilic immunomodulator, 
in in vitro skin permeation and in vivo therapeutic efficacy. 
Therefore, the HST-loaded EL/T formulation developed 
in this study can be used to treat AD as an alternative to ste-
roid therapy, which is very limited for long-term application 
due to the severe side effects.
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